Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
Rhea-AI Summary
Acrivon Therapeutics (Nasdaq: ACRV) will release clinical updates via press release at 7:30 a.m. ET and host a conference call and webcast at 8:30 a.m. ET on Thursday, January 8, 2026.
Planned disclosures include updated interim ACR-368 clinical data from the ongoing registrational-intent Phase 2b study, an update on a recently initiated tumor biopsy-independent Phase 2b arm, and details on the planned confirmatory Phase 3 trial. The company will also present initial Phase 1 data for ACR-2316 (WEE1/PKMYT1 inhibitor) covering safety, dosing regimen, and early clinical activity across AP3-prioritized solid tumors, plus nomination of a new preclinical development candidate in the AP3-driven cell cycle program.
A live webcast will be available from the company’s Events & Presentations page at https://ir.acrivon.com/news-events/events-presentations.
Positive
- None.
Negative
- None.
News Market Reaction 76 Alerts
On the day this news was published, ACRV gained 31.44%, reflecting a significant positive market reaction. Argus tracked a peak move of +48.1% during that session. Our momentum scanner triggered 76 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $27M to the company's valuation, bringing the market cap to $112M at that time. Trading volume was exceptionally heavy at 5.6x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ACRV’s -6.91% decline contrasts with mixed peers: TPST -6%, PSTV -1.32%, RADX -1.92%, while RENB +19.33% and TELO +8.76% gained, pointing to stock-specific dynamics.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 17 | Clinical update notice | Positive | -4.5% | Announced January 2026 webcast with ACR-368 and ACR-2316 updates. |
| Dec 17 | Clinical update notice | Positive | -4.5% | Outlined plans for updated ACR-368 data and initial ACR-2316 results. |
| Nov 13 | Earnings and pipeline | Positive | -9.2% | Reported Q3 2025 results, cash of $134.4M and clinical progress. |
| Oct 22 | Preclinical data | Positive | -2.5% | Shared AP3-based preclinical data and early clinical activity for ACR-2316. |
| Oct 01 | Inducement grant | Neutral | +0.0% | Granted 225,000 stock options to new executive under Nasdaq rules. |
Recent clinical and earnings updates with generally constructive content have often been followed by negative price reactions.
Over the last few months, Acrivon highlighted progress across ACR-368 and ACR-2316, including a registrational-intent Phase 2b program, initial clinical activity signals, and preclinical AP3 platform data. An inducement option grant on Oct 01, 2025 saw no price impact. Earnings on Nov 13, 2025 detailed a net loss of $18.2M and cash of $134.4M, yet shares fell. Prior clinical-trial communication on Dec 17, 2025 about the same upcoming January 2026 updates also coincided with a negative move, consistent with today’s reaction.
Market Pulse Summary
The stock surged +31.4% in the session following this news. A strong positive reaction aligns with anticipation around upcoming ACR-368 and ACR-2316 data after prior clinical headlines averaged moves of about 3.85%. Historically, even constructive updates on this name sometimes saw negative follow-through, so any sharp upside could reflect changing sentiment or positioning. Investors might watch how the detailed January 8, 2026 readouts compare with earlier signals like the 35% ORR and 80% tumor shrinkage.
Key Terms
generative phosphoproteomics medical
wee1/pkmyt1 inhibitor medical
AI-generated analysis. Not financial advice.
Company to host conference call and webcast at 8:30 a.m. ET on Thursday, January 8, 2026
WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-regulated effects in the intact cell which is deployed for rational drug design and predictive clinical development, today announced it will be providing ACR-368 and ACR-2316 clinical data and other updates via a press release at 7:30 a.m. ET, and conference call and webcast at 8:30 a.m. ET, both on Thursday, January 8, 2026.
Topics will include:
- Updated interim ACR-368 clinical data from the ongoing registrational-intent Phase 2b study as well as an update on the additional recently initiated tumor biopsy-independent Phase 2b arm, and the planned confirmatory Phase 3 trial
- Initial clinical data from the ongoing Phase 1 study of ACR-2316, a potential first- and best-in-class WEE1/PKMYT1 inhibitor, including safety data, dosing regimen, and early clinical activity across AP3-prioritized solid tumor types
- Nomination of new preclinical development candidate, including target disclosure, for Acrivon’s AP3-driven cell cycle program
A live webcast of the event will be available through a link on the Events & Presentations page within the investor section of the company’s website at https://ir.acrivon.com/news-events/events-presentations.
About Acrivon Therapeutics
Acrivon is a clinical stage biopharmaceutical company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 platform. The platform allows the company to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights. The Generative Phosphoproteomics AP3 platform is comprised of a growing suite of powerful, internally-developed tools, including the AP3 Data Portal, converting multimodal data into structured data for generative AI analyses, the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome. These distinctive capabilities enable the company to go beyond the limitations of traditional drug discovery, as well as current AI-based target-centric drug discovery, and rapidly design highly differentiated compounds with desirable pathway effects through intracellular protein network analyses and advance these agents into the clinic for streamlined development.
Acrivon is currently advancing its lead program, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2b trial for endometrial cancer. The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as a monotherapy based on OncoSignature-predicted sensitivity in patients with endometrial cancer. The FDA has granted a Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of patients with endometrial cancer who may benefit from ACR-368 treatment.
In addition to ACR-368, Acrivon is also leveraging its proprietary Generative Phosphoproteomics AP3 platform for developing its co-crystallography-driven, internally discovered pipeline programs. These include ACR-2316, the company’s second clinical stage asset, a novel, potent, selective WEE1/PKMYT1 inhibitor designed for superior single-agent activity through strong activation of not only CDK1 and CDK2, but also of PLK1 to drive pro-apoptotic cell death, as observed in preclinical studies against benchmark inhibitors. The Phase 1 trial of ACR-2316 is advancing with enrollment in the first three dose-escalation cohorts completed. Drug target engagement was observed at DL1 and 2 using the company’s clinical mass-spectrometry-based AP3 profiling, with evidence of approximate dose proportionality based on plasma pharmacokinetic analyses, and initial clinical activity with tumor shrinkage observed at DL3. In addition, the company is advancing a preclinical program directed against an undisclosed cell cycle regulatory target.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our preclinical and clinical results, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Acrivon’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in our reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Acrivon undertakes no duty to update such information except as required under applicable law.
Investor and Media Contacts:
Adam D. Levy, Ph.D., M.B.A.
alevy@acrivon.com
Alexandra Santos
asantos@wheelhouselsa.com
FAQ
When will Acrivon (ACRV) announce ACR-368 and ACR-2316 clinical updates?
What ACR-368 data will Acrivon (ACRV) present on January 8, 2026?
What initial results for ACR-2316 will Acrivon (ACRV) share on the webcast?
How can investors access Acrivon’s January 8, 2026 webcast for ACRV?
Will Acrivon (ACRV) discuss a Phase 3 plan for ACR-368 during the presentation?
